Risperidone
Author: Flavio Guzman, MD Competing interests: none This article summarizes the most clinically relevant features of long-acting injectable antipsychotics (LAIs, previously known as depot antipsychotics). We discuss general concepts as well as key prescribing facts of individual agents. The guide also includes two new formulations: aripiprazole lauroxil (Aristada) and 3-month paliperidone palmitate (Invega Trinza). Advantages and disadvantages of long-acting antipsychotics…
Read More
Author: Flavio Guzman, MD Risperidone is a second-generation antipsychotic metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). It is available as long-acting injection (depot injection) as well as oral formulations. This clinical summary highlights pharmacokinetic features relevant to mental health prescribers. Formulations Oral formulations: Tablets Orally disintegrating tablets Liquid formulation Long-acting injection: risperidone microspheres (Risperdal Consta) General…
Read MoreBy Flavio Guzman, MD. Risperidone is one of the oldest (and least expensive) second-generation antipsychotics. In 1993 the FDA approved it for the treatment of schizophrenia. Like most antipsychotics, risperidone is also effective for the treatment of manic and mixed episodes of bipolar I disorder. It is also one of the few antipsychotics approved for…
Read More